EUVIMEDEUVIMED entdecken
Open Access

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

Sundar Jagannath iD, Thomas G Martin, Yi Lin iD, Adam D Cohen iD, Noopur Raje iD, Myo Htut, Abhinav Deol iD, Mounzer Agha iD, Jesus G Berdeja iD, Alexander M Lesokhin, Jessica J Liegel iD, Adriana Rossi iD und 21 weitere

Journal of Clinical Oncology · 2025-09 · 43 (25) · 2766-2771

DOI: 10.1200/jco-25-00760 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025-09. Verfasst von Sundar Jagannath und 32 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive. Die Arbeit wurde bisher 161-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free outcomes, associated biomarkers, and safety, with a median study follow-up of 61.3 months. For the 97 treated patients, median OS was 60.7 months (95% CI, 41.9 to not estimable). One third (32/97) of patients remain alive and progression-free for ≥5 years after a single cilta-cel infusion, without maintenance treatment. Twelve of these patients treated at a single center underwent serial minimal residual disease (MRD) and positron emission tomography-computed tomography assessments, and all (100%) were MRD-negative (at least 10 −5 threshold) and imaging-negative at year 5 or later after cilta-cel. Baseline characteristics, including the presence of high-risk cytogenetics and extramedullary disease, were generally comparable for the 32 patients who were progression-free for ≥5 years versus patients who had progressive disease by year 5. A trend of lower baseline tumor burden, higher fraction of naïve T-cells in the cilta-cel drug product, higher T cell-to-neutrophil ratio, higher hemoglobin and platelets at baseline, and higher effector-to-target ratio were associated with ≥5-year progression-free status. The safety profile of cilta-cel remained consistent with previous reports. To our knowledge, our data provide the first evidence that cilta-cel is potentially curative in patients with RRMM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveHumansMaleFemaleMiddle AgedAgedRemission InductionAdultProgression-Free SurvivalNeoplasm Recurrence, Local

Autor:innen und Institutionen

  • Icahn School of Medicine at Mount Sinai, New York, NY.
  • University of California, San Francisco, San Francisco, CA.
  • Mayo Clinic, Rochester, MN.
  • Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Massachusetts General Hospital Cancer Center, Boston, MA.
  • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA.

ORCID-Profile: Sundar Jagannath, Yi Lin, Adam D Cohen, Noopur Raje, Abhinav Deol, Mounzer Agha, Jesus G Berdeja, Jessica J Liegel, Adriana Rossi, Alex Lieberman-Cribbin, Saad Z Usmani, Binod Dhakal, Samir Parekh, Rocio Montes de Oca, Andrzej J Jakubowiak, Peter M Voorhees

Förderung

  • NCI NIH HHS

Zitieren

APA

Jagannath, S., Martin, T. G., Lin, Y., Cohen, A. D., Raje, N., Htut, M., Deol, A., Agha, M., Berdeja, J. G., Lesokhin, A. M., Liegel, J. J., Rossi, A., Lieberman-Cribbin, A., Usmani, S. Z., Dhakal, B., Parekh, S., Li, H., Wang, F., Montes de Oca, R., …, & Voorhees, P. M. (2025). Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 43(25), 2766-2771. https://doi.org/10.1200/jco-25-00760

Vancouver

Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology. 2025;43(25):2766-2771. doi:10.1200/jco-25-00760

BibTeX
@article{Jagannath2025,
  author = {Jagannath, Sundar and Martin, Thomas G and Lin, Yi and Cohen, Adam D and Raje, Noopur and Htut, Myo and Deol, Abhinav and Agha, Mounzer and Berdeja, Jesus G and Lesokhin, Alexander M and Liegel, Jessica J and Rossi, Adriana and Lieberman-Cribbin, Alex and Usmani, Saad Z and Dhakal, Binod and Parekh, Samir and Li, Hui and Wang, Feng and Montes de Oca, Rocio and Plaks, Vicki and Sun, Huabin and Banerjee, Arnob and Schecter, Jordan M and Lendvai, Nikoletta and Madduri, Deepu and Lengil, Tamar and Zhu, Jieqing and Koneru, Mythili and Akram, Muhammad and Patel, Nitin and Costa Filho, Octavio and Jakubowiak, Andrzej J and Voorhees, Peter M},
  title = {Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {25},
  pages = {2766--2771},
  doi = {10.1200/jco-25-00760}
}
Kostenlos starten →